article thumbnail

Novo’s obesity drug has serious warnings and barriers to overcome

World of DTC Marketing

Can diabetes patients really stay adherent to a drug for 63 weeks in which 85% of patients report GI side effects and will insurance cover the cost? Wegovy’s most common side effects were gastrointestinal problems, including nausea, diarrhea, and vomiting which was reported by 80% of patients according to USA Today.

article thumbnail

Study finds no link between Novo Nordisk’s GLP-1 drugs and suicidal ideation

Fierce Pharma

Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one of them suicide ideation—a study of medi | Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Metformin helps manage weight gain side effect of SGAs

European Pharmaceutical Review

SGAs used to treat bipolar disorder are often effective at helping young patients’ mental health improve but can have significant side effects including elevated blood pressure and glucose, increased appetite, as well as weight gain.

article thumbnail

DTC Study: Marketers misaligned with online health seeker needs

World of DTC Marketing

It’s more about weighing the benefit against the potential side effects. Still, we’re finding that people are more interested in potential “side effects,” especially a side effect that compromises their immune system or causes GI upset. In the past, the cost was a key issue.

article thumbnail

Preventative approach could reduce immunotherapy side effects

European Pharmaceutical Review

Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). The post Preventative approach could reduce immunotherapy side effects appeared first on European Pharmaceutical Review.

article thumbnail

CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug

MedCity News

Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as chronic pain and bipolar disorder.

article thumbnail

How Artificial Intelligence Could Be the Ultimate Weapon Against Cancer

MedCity News

AI algorithms can analyze medical images and identify any abnormalities that may indicate cancer. In a study conducted by Korean academic hospitals and Lunit, a medical AI company specializing in developing AI solutions for radiology and oncology, the algorithm outperformed human radiologists in identifying breast cancer.